Connection

DAVID POPLACK to Neoplasms

This is a "connection" page, showing publications DAVID POPLACK has written about Neoplasms.
Connection Strength

1.174
  1. Addressing the childhood cancer crisis in sub-Saharan Africa. Lancet Oncol. 2023 07; 24(7):729-732.
    View in: PubMed
    Score: 0.302
  2. Childhood cancer survivor care: development of the Passport for Care. Nat Rev Clin Oncol. 2014 12; 11(12):740-50.
    View in: PubMed
    Score: 0.166
  3. Reply to "childhood cancer in Africa". Pediatr Blood Cancer. 2014 Aug; 61(8):1524.
    View in: PubMed
    Score: 0.158
  4. Clinician perceptions of Passport for Care, a web-based clinical decision support tool for survivorship care plan delivery. Pediatr Blood Cancer. 2023 01; 70(1):e30070.
    View in: PubMed
    Score: 0.072
  5. An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. Pediatr Hematol Oncol. 2018 Mar; 35(2):95-110.
    View in: PubMed
    Score: 0.053
  6. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995 Sep 15; 55(18):4069-72.
    View in: PubMed
    Score: 0.044
  7. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol. 1993 Sep; 11(9):1795-803.
    View in: PubMed
    Score: 0.038
  8. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
    View in: PubMed
    Score: 0.037
  9. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res. 1992 Feb 01; 52(3):521-4.
    View in: PubMed
    Score: 0.034
  10. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res. 1990 Aug 01; 50(15):4464-7.
    View in: PubMed
    Score: 0.031
  11. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol. 1990; 26(5):343-4.
    View in: PubMed
    Score: 0.030
  12. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res. 1985 Sep; 45(9):4156-61.
    View in: PubMed
    Score: 0.022
  13. Introduction: pediatric oncology. Cancer J. 2005 Jul-Aug; 11(4):253-4.
    View in: PubMed
    Score: 0.022
  14. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63.
    View in: PubMed
    Score: 0.021
  15. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst. 2004 Oct 20; 96(20):1557-9.
    View in: PubMed
    Score: 0.021
  16. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
    View in: PubMed
    Score: 0.013
  17. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
    View in: PubMed
    Score: 0.013
  18. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl. 1998; 11:48-51.
    View in: PubMed
    Score: 0.013
  19. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43.
    View in: PubMed
    Score: 0.012
  20. A phase II study of thioTEPA in children with recurrent solid tumor malignancies: a Children's Cancer Group study. Invest New Drugs. 1996; 13(4):337-42.
    View in: PubMed
    Score: 0.011
  21. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor. Cancer Res. 1993 Jun 01; 53(11):2587-90.
    View in: PubMed
    Score: 0.009
  22. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992 Feb; 11(2):111-8.
    View in: PubMed
    Score: 0.009
  23. [Infectious complications from intraventricular route of administration in cancer patients]. Probl Med Wieku Rozwoj. 1990; 16:45-53.
    View in: PubMed
    Score: 0.007
  24. Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res. 1989 Sep 15; 49(18):5213-6.
    View in: PubMed
    Score: 0.007
  25. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 1989 Mar 15; 49(6):1422-8.
    View in: PubMed
    Score: 0.007
  26. Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J. 1987 Feb; 6(2):182-9.
    View in: PubMed
    Score: 0.006
  27. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan; 84(1):265-9.
    View in: PubMed
    Score: 0.006
  28. Pregnancy outcome following cancer chemotherapy. Am J Med. 1980 Dec; 69(6):828-32.
    View in: PubMed
    Score: 0.004
  29. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med. 1979 Aug; 67(2):194-200.
    View in: PubMed
    Score: 0.004
  30. Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res. 1991 Jun 15; 51(12):3171-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.